CASI Pharmeceuticals

MARQIBO®

Marqibo

7 March 2019

CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®


Marqibo® (vinCRIStine sulfate LIPOSOME injection) is a novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor. Marqibo is approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Please see Marqibo product and safety information.

Since MARQIBO is already approved in the U.S. and marketed by our licensor, we expect that gaining approval from local regulatory authorities for commercialization in greater China will require a shorter timeframe than clinical stage drugs. We submitted an import drug registration is pending with CFDA.

About Us

CASI is a U.S. NASDAQ-listed pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which substantially all of our operations are conducted.

Learn More

Presentation

Corporate Presentation - BIO CEO & Investor Conference

Download →

Presentation

Annual Meeting Presentation

Download →